Table 3. Adverse Effects in 16 Patientsa.
| Adverse Effect | Data |
|---|---|
| Elevated reticulocyte count, No. (%) | 4 (5) |
| Increase in reticulocyte count, % | |
| Mean (SD) | 4.8 (2.5) |
| Median (range) | 3.6 (2.9-9.0) |
| Decreased hemoglobin level, No. (%) | 3 (4) |
| Decrease in hemoglobin level, g/dL | |
| Mean (SD) | 2.8 (0.6) |
| Median (range) | 3.0 (2.0-3.4) |
| Dizziness or light-headedness, No. (%) | 4 (5) |
| Fatigue, No. (%) | 3 (4) |
| Dyspnea, No. (%) | 2 (2) |
| Elevated liver transaminase enzyme levels, No. (%) | 2 (2) |
| Gastrointestinal tract symptoms, No. (%) | 1 (1) |
| Decreased white blood cell count, No. (%) | 1 (1) |
| Methemoglobinemia, No. (%)b | 1 (1) |
| DRESS, No. (%) | 1 (1) |
Abbreviation: DRESS, drug reaction with eosinophilia and systemic symptoms.
SI conversion factors: To convert hemoglobin to grams per liter, multiply by 10.0; reticulocyte count to proportion of red blood cells, multiply by 0.01.
a
Sixteen patients experienced 22 total adverse effects; 5 experienced more than 1 adverse effect.
b
Methemoglobinemia was 8%, with associated chills, myalgia, and fatigue and was accompanied by a 3.6 g/dL decrease in hemoglobin and 5.2% increase in reticulocyte count at the time of discontinuing dapsone therapy.